Furthermore, CD200 MFI refined the prognostication based on conventional CLL risk factors, which suggested that addition of CD200 MFI to classical prognostic factors should improve the risk stratification in patients with CLL. The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.